Nutex Health (NASDAQ:NUTX) Stock Price Down 4.7% – Should You Sell?

Nutex Health Inc. (NASDAQ:NUTX)’s stock price traded down 4.7% during trading on Wednesday . The company traded as low as $118.50 and last traded at $120.4580. 89,092 shares traded hands during trading, a decline of 54% from the average session volume of 192,946 shares. The stock had previously closed at $126.39.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the company. Weiss Ratings upgraded Nutex Health from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday, May 4th. Wall Street Zen upgraded Nutex Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $205.00.

Nutex Health Price Performance

The stock has a fifty day moving average price of $107.37 and a 200-day moving average price of $127.79. The company has a market cap of $835.31 million, a PE ratio of 9.38 and a beta of 0.25. The company has a debt-to-equity ratio of 0.66, a current ratio of 3.14 and a quick ratio of 3.12.

Nutex Health (NASDAQ:NUTX) last posted its quarterly earnings results on Thursday, April 30th. The company reported $6.52 earnings per share for the quarter, topping analysts’ consensus estimates of $3.99 by $2.53. Nutex Health had a net margin of 10.95% and a return on equity of 23.50%. The business had revenue of $216.49 million for the quarter, compared to the consensus estimate of $227.80 million.

Hedge Funds Weigh In On Nutex Health

Several institutional investors have recently bought and sold shares of the stock. Topline Capital Management LLC raised its holdings in Nutex Health by 80.0% during the third quarter. Topline Capital Management LLC now owns 556,567 shares of the company’s stock valued at $57,505,000 after buying an additional 247,436 shares in the last quarter. Pertento Partners LLP raised its holdings in Nutex Health by 20.0% during the fourth quarter. Pertento Partners LLP now owns 324,422 shares of the company’s stock valued at $53,406,000 after buying an additional 54,001 shares in the last quarter. Vanguard Group Inc. raised its holdings in Nutex Health by 12.7% during the third quarter. Vanguard Group Inc. now owns 214,954 shares of the company’s stock valued at $22,209,000 after buying an additional 24,275 shares in the last quarter. Millennium Management LLC raised its holdings in Nutex Health by 191.1% during the third quarter. Millennium Management LLC now owns 93,396 shares of the company’s stock valued at $9,650,000 after buying an additional 61,308 shares in the last quarter. Finally, State Street Corp grew its position in shares of Nutex Health by 11.6% in the fourth quarter. State Street Corp now owns 86,792 shares of the company’s stock valued at $14,288,000 after purchasing an additional 9,052 shares during the last quarter. 5.32% of the stock is currently owned by institutional investors.

Nutex Health Company Profile

Nutex Health, Inc (NASDAQ: NUTX) is an integrated outpatient healthcare services company based in San Antonio, Texas. The company focuses on delivering a range of ambulatory care solutions, including urgent care, telemedicine, medical imaging, teleradiology, weight‐loss services and behavioral health support. By combining in‐person clinics with virtual care capabilities, Nutex Health aims to provide patients with accessible, cost‐effective treatment options outside traditional hospital settings.

The company’s urgent care network operates through both standalone and retail‐anchored centers, offering treatment for non‐life‐threatening injuries and illnesses, preventive screenings and basic primary care.